Loading viewer...
investor_presentation
Format: PDF investor_presentation
Helix BioPharma is developing L-DOS47, a novel first-in-class tumor microenvironment modifying drug designed to break tumor defense against the immune system. The drug has demonstrated good tolerability and safety in over 100 patients with NSCLC and PDAC, showing promising results in combination with chemotherapy and checkpoint inhibitors. A 2023 funding round of $10M will support preclinical experiments toward partnership opportunities.
investor_presentation
22 Pages
Pfizer
Vinhomes 2Q 2022 Investor Presentation
investor_presentationinvestor_presentation
31 Pages
Vinhomes Joint Stock Company